Answers go deeper than the script

Boston Scientific Corporation (BSX) — this company's answers

The model's full reasoning — Q1 2022 call → NOWe need to evaluate two gates based on the transcript. Gate 1: Is there a positive current development that management presents as going well, and in Q&A, management adds more concrete operating detail than in prepared remarks? We need to see if across multiple exchanges, management provides additive specifics. Gate 2: Is the primary engine of that development something the company itself created and controls, not external environment? Let's analyze the transcript. Prepared remarks: Mike Mahoney highlights Q1 performance, growth across regions, business units. Mentions WATCHMAN growth 33%, FARAPULSE, etc. Also mentions acquisitions, etc. In Q&A, analysts ask about various things. Let's see if any positive development gets more detail. First question from Robbie Marcus: asks about Q2 guidance and China lockdowns, then asks about WATCHMAN growth and competitive landscape. Mike responds about WATCHMAN: "It's really consistent with previous orders... primary growth driver is US... new account openings, driving increased utilization... support with clinical trials and excellent results... new products coming behind WATCHMAN." He mentions data from SURPASS, etc. But is this additive? He mentions "16,000 SURPASS data" in prepared remarks? Actually in prepared remarks he said "ongoing surpass analysis of the NCDR LAAO registry was presented at CRT, including more than 16,000 patients" so that was already mentioned. In Q&A, he adds "more physicians using the device, more referring physicians seeing excellent results" but that's somewhat generic. He also mentions "new clinical trials" but not specific. So not much new concrete detail. Next question from Rick Wise: asks about integrating deals, specifically FARAPULSE production ramp. Mike gives details about each acquisition: Preventice, LUMINIZE, Baylis, FARAPULSE, Devoro. He mentions "we've also just done our first patients using Baylis and WATCHMAN" - that's a specific new detail. Also for FARAPULSE, he says "we anticipate a really strong second half ramp consistent we've said in the past in Europe this year with FARAPULSE" and "that trial is enrolling incredibly well." Then Ken Stein adds more about FARAPULSE: "we've done over 3,000 commercial cases in Europe already" and "MANIFEST-PF survey reported over 1,700 cases" and "99.9% acute success" and "outstanding total procedure times" and "no esophageal injury" etc.

The model's full reasoning — Q3 2017 call → NOWe need answer only YES or NO. Need evaluate both gates. Need use transcript. Gate 1: positive current development, Q&A adds more concrete operating detail than prepared remarks, multiple exchanges additive substantive. Gate 2: improvement filter: development chiefly company-created/controlled, not external. Need identify main positive current development probed. Candidates: LOTUS/TAVR? WATCHMAN? CRM/Resonate? ACURATE? China? Need see Q&A. Prepared remarks: strong results, WATCHMAN, ACURATE, LOTUS timelines, CRM Resonate, etc. Q&A: - David Lewis asks about Q4 momentum and 2018 assumptions, then LOTUS delay. Mike answers: U.S. timeline unchanged, Europe delay due to scalability operations/quality. No new concrete operating detail? Maybe. - Mike Weinstein asks LOTUS scalability, risk another delay. Mike says comfortable, no delay U.S., exceeded Structural Heart guidance, 90-day delay Europe. Not much new. - Bob Hopkins asks LOTUS what changed, Ian answers: PMA modules, clinical module submitted, technical by year-end/Jan, Europe notified body, MDR. Some detail but not really operations? Then asks China outlook and NCD. Mike answers China growth, diversification, volume offset price. Ken answers NCD. This is positive current development? China growth is current, but Q&A adds? Mike says China up 18% Emerging, 20% China, diversification, volume offset price. Prepared remarks already said Emerging 18%, China 23%. Q&A adds "tendering" and "volume and distribution reach offset price" but not much concrete. NCD is future. - Rick Wise asks ACURATE neo performance, countries, market share, next. Mike says Symetis outperformed, expanding, direct sales force, more guidance later. Ian adds SCOPE I/II enrollment timelines, JACC publication, U.S. IDE planned. This is additive? It gives clinical trial details, but not current operating detail? It is about ACURATE current performance? Prepared remarks already said strong clinical/commercial, ACURATE strong growth, JACC publication. Q&A adds trial enrollment timelines and U.S. IDE planned. But is that "concrete operating detail" about current development? Maybe some. - Glenn Novarro asks ICD franchise MRI safe approved, growth, replacement headwind. Mike says bullish, Resonate platform, HeartLogic, longevity, S-ICD, expect faster growth Q4/2018, replacement tailwind. This is mostly forward-looking, not current concrete.

The model's full reasoning — Q2 2021 call → NOWe need to evaluate both gates based on the transcript. Gate 1: Is there a positive, current development that management presents as going well, and does the Q&A produce more concrete operating detail than the prepared remarks? The prepared remarks mention many positive things: strong Q2 results, WATCHMAN growth, neuromodulation, etc. The Q&A probes several areas. Let's see if any development gets more detail in Q&A. - WATCHMAN: In prepared remarks, Mike says WATCHMAN growth driven by utilization, FLX conversion, etc. In Q&A, Bob Hopkins asks about WATCHMAN trends. Mike gives more detail: U.S. fully converted, OPTION trial enrolled ahead, utilization rates, physician training, referral base, expects plus 30% growth. That's more specific than prepared remarks? Prepared remarks already said "nearly all U.S accounts have fully transitioned" and "OPTION trial recently completed enrollment ahead of schedule." Q&A adds "plus 30% growth" and more about drivers. But is that substantially more? It's somewhat additive. - Neuromodulation: In Q&A, Cecilia asks about SCS trialing trends and Vertiflex. Mike gives detail about SCS improvement, RF portfolio, DBS growth, market share. That's more than prepared remarks? Prepared remarks mentioned WaveWriter, COMBO study, SOLIS, etc. Q&A adds specifics about DBS being number one de novo in Europe, etc. That's additive. - EXALT D: In Q&A, Pito asks about EXALT D accounts, market share, reorder rate. Mike says they are not prepared to share that information, but gives some general progress. That's not additive; it's deflection. - EP and CRM: In Q&A, Joanne asks about EP and CRM lagging. Mike gives detail about EP international growth, cryo, STABLEPOINT, Farapulse, and CRM S-ICD advisory impact and new lead. That's more detail than prepared remarks? Prepared remarks mentioned EP international growth, S-ICD advisory, new electrode. Q&A adds more about the dynamics. But the question is: Is there a single positive development that analysts probe and management adds concrete operating detail across multiple exchanges? The Q&A has multiple questions but each focuses on different topics. The WATCHMAN question gets one answer. The neuromod question gets one answer. The EP/CRM question gets one answer. There isn't a single development that is probed across multiple exchanges with additive detail. Each is a single exchange.

← Back to the full BSX analysis